Eika S. Webb, Peng Liu, Renato Baleeiro, Nicholas R. Lemoine, Ming Yuan, Yaohe Wang. Immune checkpoint inhibitors in cancer therapy[J]. The Journal of Biomedical Research, 2018, 32(5): 317-326. DOI: 10.7555/JBR.31.20160168
Citation:
Eika S. Webb, Peng Liu, Renato Baleeiro, Nicholas R. Lemoine, Ming Yuan, Yaohe Wang. Immune checkpoint inhibitors in cancer therapy[J]. The Journal of Biomedical Research, 2018, 32(5): 317-326. DOI: 10.7555/JBR.31.20160168
Eika S. Webb, Peng Liu, Renato Baleeiro, Nicholas R. Lemoine, Ming Yuan, Yaohe Wang. Immune checkpoint inhibitors in cancer therapy[J]. The Journal of Biomedical Research, 2018, 32(5): 317-326. DOI: 10.7555/JBR.31.20160168
Citation:
Eika S. Webb, Peng Liu, Renato Baleeiro, Nicholas R. Lemoine, Ming Yuan, Yaohe Wang. Immune checkpoint inhibitors in cancer therapy[J]. The Journal of Biomedical Research, 2018, 32(5): 317-326. DOI: 10.7555/JBR.31.20160168
Center for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, EC1M 6BQ, UK
2.
Sino-British Research Centre for Molecular Oncology, National Center for International Research in Cell and Gene Therapy, Zhengzhou University, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450002, China.
Funds:
This work was supported by The MRC DPFS grant (MR/M015696/1) and Ministry of Sciences and Technology of China (2013DFG32080).
In recent years immune checkpoint inhibitors have garnered attention as being one of the most promising types of immunotherapy on the horizon. There has been particular focus on the immune checkpoint molecules, cytotoxic Tlymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) which have been shown to have potent immunomodulatory effects through their function as negative regulators of T cell activation. CTLA-4, through engagement with its ligands B7-1 (CD80) and B7-2 (CD86), plays a pivotal role in attenuating the activation of na?ve and memory T cells. In contrast, PD-1 is primarily involved in modulating T cell activity in peripheral tissues via its
interaction with PD-L1 and PD-L2. The discovery of these negative regulators of the immune response was crucial in the development of checkpoint inhibitors. This shifted the focus from developing therapies that targeted activation of the host immune system against cancer to checkpoint inhibitors, which aimed to mediate tumor cell destruction through the removal of coinhibitory signals blocking anti tumor T cell responses.
Hickerson BT, Khalenkov AM, Xie T, et al. Interchangeability of the Assays Used to Assess the Activity of Anti-SARS-CoV-2 Monoclonal Antibodies. Viruses, 2023, 15(8): 1698.
DOI:10.3390/v15081698
1.
Hickerson BT, Khalenkov AM, Xie T, et al. Interchangeability of the Assays Used to Assess the Activity of Anti-SARS-CoV-2 Monoclonal Antibodies. Viruses, 2023, 15(8): 1698.
DOI:10.3390/v15081698